BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, January 1, 2026
See today's BioWorld MedTech
Home
» Inside the Beltway: AdvaMed: IDE benefit-risk draft's use of 'well-designed' term too squishy
To read the full story,
subscribe
or
sign in
.
Inside the Beltway: AdvaMed: IDE benefit-risk draft's use of 'well-designed' term too squishy
Sep. 25, 2015
By
Mark McCarty
BioWorld MedTech